Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT101a in Relapsed or Refractory AML
NCT05256277Phase 1Terminated
- Sponsor
- Zhejiang University
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT101A in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoint: Dose Limiting Toxicity / Maximum Tolerated Dose at 28 days. Started Dec 2021; status: terminated.
02
Drugs
CT101A
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05256277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256277.